Home
Resources
Publications
[Employing Tyrosine Kinase Inhibitors in the First Line Treatment of EGFR-positive Metastatic NSCLC - State of the Art and Recent Developments]

[Employing Tyrosine Kinase Inhibitors in the First Line Treatment of EGFR-positive Metastatic NSCLC - State of the Art and Recent Developments]

R Wiewrodt, M Serke, C Grohé, W Brückl

Pneumologie. 2013 Sep;67(9):494-501.

PMID: 24006195

Abstract:

In this review article we present an overview of recent developments in EGFR TKIs in lung cancer therapy. Besides the approved drugs erlotinib and gefitinib, clinical data on second-generation irreversible TKIs including afatinib, dacomitinib, neratinib, pelitinib, and canertinib are mentioned; these drugs not only inactivate EGFR but show a broader range of activity. We also report on NSCLC data of TKI that are known and approved in other indications, such as lapatinib and vandetanib. We stress the importance of quality of life in the treatment of patients with TKIs, an important aspect of the treatment that should also be considered in the selection of the appropriate NSCLC therapy in advanced stages.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP257933827	Pelitinib		257933-82-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: